Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study

Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study

Background The effects of sacubitril/valsartan in patients with chronic heart failure with reduced ejection fraction (HFrEF) were recently reported. However, the hemodynamic impact of this well-established treatment in patients with HFrEF has been poorly systematically researched. Aim We aimed to in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of cardiovascular drugs : drugs, devices, and other interventions devices, and other interventions, 2022-09, Vol.22 (5), p.535-544
Hauptverfasser: Abumayyaleh, Mohammad, Demmer, Jonathan, Krack, Carina, Pilsinger, Christina, El-Battrawy, Ibrahim, Behnes, Michael, Aweimer, Assem, Mügge, Andreas, Lang, Siegfried, Akin, Ibrahim
Format: Artikel
Sprache:eng
Schlagworte:
Cardiac arrhythmia
Cardiology
Cardiomyopathy
Cardiovascular disease
Clinical outcomes
Diabetes
Ejection fraction
Heart failure
Hemodynamics
Hospitalization
Hypertension
Medical prognosis
Medicine
Medicine & Public Health
Mortality
Normal distribution
Original
Original Research Article
Pharmacology/Toxicology
Pharmacotherapy
Pulmonary arteries
Survival analysis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The effects of sacubitril/valsartan in patients with chronic heart failure with reduced ejection fraction (HFrEF) were recently reported. However, the hemodynamic impact of this well-established treatment in patients with HFrEF has been poorly systematically researched. Aim We aimed to investigate the hemodynamic effects of sacubitril/valsartan among patients with HFrEF. Methods Between 2016 and 2020, we retrospectively collected data for patients with HFrEF treated at the University Medical Center Mannheim, Germany. Data for 240 patients with HFrEF were available. We systematically analyzed echocardiographic parameters, all-cause hospitalization, and congestion rate. Results The left ventricular ejection fraction (LVEF) improved from a median (minimum; maximum) of 28% (3; 65) before initiation of sacubitril/valsartan to a median of 34% (13; 64) at 24-month follow-up ( p  
ISSN:1175-3277
1179-187X
DOI:10.1007/s40256-022-00525-w